Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Nitroprusside vs. Dobutamine in Acute Decompensated Heart Failure (PRIORITY-ADHF)
NCT02767024Phase 4Withdrawn
- Sponsor
- Montefiore Medical Center
- Start
- May 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sodium nitroprusside in Acute Heart Failure (AHF) (2 arms), sponsored by Montefiore Medical Center. Primary endpoints: Arrhythmia incidence at 72 hours, Serum troponin T release at 72 hours and 1 more. Planned start May 2018; status: withdrawn.
02
Drugs
sodium nitroprusside
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT02767024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767024.